Evaxion Biotech A/S (EVAX)
Chart Events
Performance Outlook
| Previous Close | 5.48 |
| Open | 5.62 |
| Bid | 5.30 x 1100 |
| Ask | 5.40 x 1000 |
| Day's Range | 5.39 - 5.67 |
| 52 Week Range | 5.16 - 10.34 |
| Volume | 29,891 |
| Avg. Volume | 78,879 |
| Market Cap | 103.673M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Benzinga
Evaxion's Cancer Immunotherapy Shows Antitumor Effect In Early-Stage Melanoma Study
Evaxion Biotech A/S (NASDAQ: EVAX) has announced results from its Phase 1/2a trial of EVX-01 in metastatic melanoma. Data from the trial showed that EVX-01 in combination with a PD-1 checkpoint inhibitor was safe, with only mild and moderate adverse events observed. Combined therapy with EVX-01 demonstrated an objective response rate of 67% across all nine patients, including 22% Complete Response (CR) and 44% Partial Response (PR). Among the four patients on the highest two doses, there was an
- TipRanks
Investing in AI Healthcare; Analysts Offer 2 Stocks to Buy
Let’s talk a bit about artificial intelligence, AI. It’s serious tech, and not just science fiction anymore. AI underlies the machine learning processes that are powering information technology, allowing computer systems to adapt to change and increase the speed and accuracy of their information processing. And the profits involved in AI, as it expands through the economy, will be immense. It’s estimated that AI as a whole will boost the global economy by more than $15 trillion by the year 2030,
- Insider Monkey
Is Evaxion Biotech A/S (EVAX) A Good Stock To Buy?
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F filings […]
